Dabrafenib mesylate,
1195768-06-9,
UNII-B6DC89I63E,
Dabrafenib (Mesylate),
GSK 2118436B,
METHANE SULFONATE SALT,
Dabrafenib mesylate [USAN],
B6DC89I63E,
CHEBI:75048,
GSK2118436B,
GSK-2118436B,
Dabrafenib Mesylate (GSK-2118436B),
Dabrafenib Mesylate (GSK-2118436),
Dabrafenib mesylate (USAN),
Taflinar,
N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide methanesulfonate,
GSK-2118436A,
Dabrafenib methanesulfonate,
Tafinlar (TN),
GSK2118436 Methane sulfonate salt,
dabrafenib monomesylate,
Dabrafenib mesilate (JAN),
GSK2118436 Mesylate,
GSK 2118436 Mesylate,
SCHEMBL1127269,
CHEMBL2105729,
DTXSID70152500,
YKGMKSIHIVVYKY-UHFFFAOYSA-N,
AOB87316,
BCP04738,
EX-A1559,
HY-14660A,
MFCD20922872,
AKOS025396661,
API0024336,
CS-1641,
Dabrafenib Mesylate(GSK-2118436B),
KS-00000T33,
AK174048,
AS-17010,
SC-14698,
AK00739757,
FT-0696677,
D10104,
SR-01000941590,
SR-01000941590-1,
GSK2118436 Ms salt, Dabrafenib Ms salt, GSK2118436A Ms salt,
Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, methanesulfonate (1:1),
N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic acid,
N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonate,
N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonate,
Tafinlar,
(R)-Monophos,
GSK 2118436,
1195768-06-9 (mesylate),
ACN-041337,
GSK-2118436,
A15059,